Chris Lau

Chris Lau

Expertise: Technology, Biotech

Expertise:

Technology
Biotech

Education:

Bachelor of Science
Project Management Professional

Awards and Accomplishments:

Top 100 Tipranks 2015-2021

About Chris:

Chris has over two decades of investing experience. He is an Honors B.Sc graduate (with distinction) in Science and Economics. He holds a Project Management Professional designation

Chris focuses on the technology, cyclical, and healthcare sector. He runs a newsletter with speculative Triple-baggers.

His investment strategy is based on finding undervalued stocks trading at a steep discount to their intrinsic value.

Follow Chris on DIY Value Investing.

Recent Articles

Why Cronos Has Too Many Red Flags That Should Scare Investors Away

Cronos lacks any positive catalysts ahead, other than holding Altria’s billions of cash in investments

Exxon Stock Will Reward You If You Can Time the Cycle Right

XOM stock needs a jolt in the form of higher oil prices driven by stronger demand, before the cycle turns upward.

7 Companies to Invest In Ahead of Q4 for Long-term Returns

Volatility is worsening ahead of the U.S. elections, so here are 7 companies to invest in rather than getting discouraged.

Snowflake Due to Settle Down Any Day Now

Snowflake is bound to expand its addressable market through to 2023 and investors are willing to pay too much for it.

Make Your Play Soon, Because Lockheed Martin Stock Is on the Verge of a Breakout

LMT Stock is in value territory after the company raised dividends and increased the stock buyback.

Buy JFrog First If the Technology Sector Dips

Look at FROG stock, even though it is one of many cloud computing firms for tech investors but with a very compelling DevOps that sets it apart the competition.

7 Dividend Stocks Perfect for a Retiree’s Portfolio

Chasing high yields alone will ruin an income investor’s returns, so we look at these picks that offer a balance of stability and dividend income growth.

Why Investors Should Accumulate Fastly Stock From Here

FSLY stock is still hot as TikTok-Oracle deal presses on, raising the prospects of Content Delivery Network suppliers.

Why Betting Now on Luckin Stock Might Pay Off

Luckin stock rallied in the last week but the markets will not notice because it trades on the over-the-counter market.

Speculate on Inovio and Covid-19 Vaccine Developers

After bottoming at $10 earlier this month, investor interest soared in the last week for INO stock and the company's DNA medicine.